Ravulizumab News
Ravulizumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Ravulizumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with...
- Evidence level: L5
- Predicted indications (20):
- autosomal recessive severe congenital neutropenia due to G6PC3 deficiency (100.0%)
- cyclic hematopoiesis (99.9%)
- primary hyperoxaluria (99.9%)
- severe congenital neutropenia (99.9%)
- autosomal recessive severe congenital neutropenia due to CXCR2 deficiency (99.9%)
- primary immunodeficiency syndrome due to p14 deficiency (99.8%)
- pseudo-von Willebrand disease (99.8%)
- X-linked severe congenital neutropenia (99.8%)
- primary release disorder of platelets (99.8%)
- megaloblastic anemia (disease) (99.8%)
- autosomal recessive severe congenital neutropenia due to JAGN1 deficiency (99.8%)
- cold agglutinin disease (99.8%)
- autosomal recessive severe congenital neutropenia due to CSF3R deficiency (99.8%)
- adult idiopathic neutropenia (99.8%)
- congenital neutropenia-myelofibrosis-nephromegaly syndrome (99.8%)
- Barth syndrome (99.8%)
- Glanzmann thrombasthenia (99.7%)
- primary CD59 deficiency (99.7%)
- proteinuria (99.7%)
- paroxysmal nocturnal hemoglobinuria (99.7%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.